Skip to main content
SpringerLink
Log in

Anadys Pharmaceuticals, Inc. has suspended dosing of ANA 975 in patients with hepatitis C virus infection in its ongoing phase Ib clinical trial

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Anadys Pharmaceuticals Inc.Anadys Pharmaceuticals Suspends Dosing of ANA975 in Hepatitis C Clinical Trial Pending Further Assessment of 13-Week Pre-Clinical Toxicology Studies. Media Release: 26 Jun 2006. Available from: URL: http://www.anadyspharma.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anadys Pharmaceuticals, Inc. has suspended dosing of ANA 975 in patients with hepatitis C virus infection in its ongoing phase Ib clinical trial. React. Wkly. 1109, 3 (2006). https://doi.org/10.2165/00128415-200611090-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200611090-00009

Keywords

Search

Navigation